TY - JOUR
T1 - Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease
AU - Chitnis, Shilpa
AU - Jaffery, Manall
AU - Dewey, Richard B.
N1 - Funding Information:
oraria for speaking from UCB Pharma while rotigotine was marketed in the US. Dr. Chitnis is a consultant for Medtronic and on speaker’s bureau of Medtronic, Teva, Ipsen, and Lundbeck. She has no stock ownership in any pharmaceutical company. Dr. Dewey received honoraria for speaking from UCB Pharma while rotigotine was marketed in the US. His research is funded by the National Institutes of Health, he is a speaker for Teva Neuroscience, GlaxoSmithKline, and Ipsen, and he is a consultant to Teva Neuroscience. He has no stock ownership in any pharmaceutical company. Manall Jaffery has no disclosures.
PY - 2012
Y1 - 2012
N2 - Background: When rotigotine patch was withdrawn from the US market, we prospectively gathered data on efficacy, side effects, and daytime sedation on patients while taking rotigotine and following the switch to alternate therapies. Methods: Patients rated the efficacy of rotigotine on a scale of 05 (ineffective to extremely effective) and completed the Epworth Sleepiness Scale. At a follow-up visit a mean of 3 months later, patients rated their change in efficacy and side effects on a scale of -3 to +3 (much worse to much better) and again completed the Epworth Sleepiness Scale. Results: Thirty-three patients were switched to a single alternate treatment. On rotigotine, the average efficacy score was 3.5, and after switching, the average change in efficacy was -0.67 (worsening). Average change scores for efficacy and adverse effects were 0.25 and 0.38 for levodopa, -0.88 and -0.25 for ropinirole IR, -1.2 and -0.83 for ropinirole XL, -0.80 and 1.0 for pramipexole, and -1.0 and 0.50 for rasagiline, respectively. Average change in Epworth score on each alternate agent was -3.9, -2.3, 1.3, 3.0, and 1. Conclusion: Rotigotine was an effective treatment with all groups deteriorating after switch except for the levodopa group. Fifty-eight percent of patients preferred rotigotine versus 36% preferring the alternate treatment.
AB - Background: When rotigotine patch was withdrawn from the US market, we prospectively gathered data on efficacy, side effects, and daytime sedation on patients while taking rotigotine and following the switch to alternate therapies. Methods: Patients rated the efficacy of rotigotine on a scale of 05 (ineffective to extremely effective) and completed the Epworth Sleepiness Scale. At a follow-up visit a mean of 3 months later, patients rated their change in efficacy and side effects on a scale of -3 to +3 (much worse to much better) and again completed the Epworth Sleepiness Scale. Results: Thirty-three patients were switched to a single alternate treatment. On rotigotine, the average efficacy score was 3.5, and after switching, the average change in efficacy was -0.67 (worsening). Average change scores for efficacy and adverse effects were 0.25 and 0.38 for levodopa, -0.88 and -0.25 for ropinirole IR, -1.2 and -0.83 for ropinirole XL, -0.80 and 1.0 for pramipexole, and -1.0 and 0.50 for rasagiline, respectively. Average change in Epworth score on each alternate agent was -3.9, -2.3, 1.3, 3.0, and 1. Conclusion: Rotigotine was an effective treatment with all groups deteriorating after switch except for the levodopa group. Fifty-eight percent of patients preferred rotigotine versus 36% preferring the alternate treatment.
KW - Alternate therapies
KW - Parkinson's disease
KW - Rotigotine
UR - http://www.scopus.com/inward/record.url?scp=83255176139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83255176139&partnerID=8YFLogxK
U2 - 10.3109/00207454.2011.617016
DO - 10.3109/00207454.2011.617016
M3 - Article
C2 - 21864207
AN - SCOPUS:83255176139
SN - 0020-7454
VL - 122
SP - 22
EP - 25
JO - International Journal of Neuroscience
JF - International Journal of Neuroscience
IS - 1
ER -